Bristol Myers Squibb (BMY) is trading up at $59.28 (+4.61%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on BMY
One firm's current price target on Bristol Myers Squibb: $60 — 1% above the current $59.3. Each is tracked to its date and scored the same way a member's call is.
- Wells Fargo $57.6 → $60 by Oct 2027 Oct 13, 2026 via Investing.com · Wells Fargo's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Bristol Myers Squibb revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Growth (year over year) | +17.3% | +6.9% | +8.6% | +15.9% | +62.6% | +9.1% | −0.5% | −2.5% | +7.3% | −0.2% |
| Gross profit | $14.5B | $14.7B | $16.1B | $18.1B | $30.7B | $36.4B | $36.0B | $34.3B | $34.3B | $34.3B |
| Gross margin | 74.5% | 70.7% | 71.3% | 69.1% | 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Net income | $4.46B | $1.01B | $4.92B | $3.44B | −$9.02B | $6.99B | $6.33B | $8.03B | −$8.95B | $7.05B |
| Net margin | 22.9% | 4.8% | 21.8% | 13.2% | −21.2% | 15.1% | 13.7% | 17.8% | −18.5% | 14.6% |
| EPS (diluted) | $2.65 | $0.61 | $3.01 | $2.01 | −$3.99 | $3.12 | $2.95 | $3.86 | −$4.41 | $3.46 |
| Balance sheet | ||||||||||
| Cash and equivalents | $4.24B | $5.42B | $6.91B | $12.3B | $14.5B | $14.0B | $9.12B | $11.5B | $10.3B | $10.2B |
| Total assets | $33.7B | $33.6B | $35.0B | $129.9B | $118.5B | $109.3B | $96.8B | $95.2B | $92.6B | $90.0B |
| Total liabilities | $17.4B | $21.7B | $20.9B | $78.2B | $80.6B | $73.3B | $65.7B | $65.7B | $76.2B | $71.5B |
| Long-term debt | $5.72B | $6.97B | $5.65B | $43.4B | $48.3B | $39.6B | $35.1B | $36.7B | $47.6B | $42.9B |
| Shareholders' equity | $16.2B | $11.7B | $14.0B | $51.6B | $37.8B | $35.9B | $31.1B | $29.4B | $16.3B | $18.5B |
| Cash flow | ||||||||||
| Operating cash flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.1B | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B |
| Capital expenditure | $1.22B | $1.05B | $951.0M | $836.0M | $753.0M | $973.0M | $1.12B | $1.21B | $1.25B | $1.31B |
| Free cash flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.3B | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| Dividends paid | $2.55B | $2.58B | $2.61B | $2.68B | $4.08B | $4.40B | $4.63B | $4.74B | $4.86B | $5.04B |
| Share buybacks | $231.0M | $2.47B | $320.0M | $7.30B | $1.55B | $6.29B | $8.00B | $5.16B | $0 | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.9B | $12.3B | $11.2B | $12.3B | $12.2B | $12.5B | $11.5B | $13.0B |
| Growth (year over year) | +8.4% | +7.5% | −5.6% | +0.6% | +2.8% | +1.3% | +2.6% | +5.7% |
| Gross profit | $8.94B | $7.53B | $8.17B | $8.90B | $8.79B | $8.41B | $8.07B | $9.25B |
| Gross margin | 75.1% | 61.0% | 72.9% | 72.5% | 71.9% | 67.2% | 70.2% | 71.3% |
| Net income | $1.21B | $72.0M | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B |
| Net margin | 10.2% | 0.6% | 21.9% | 10.7% | 18.0% | 8.7% | 23.3% | 25.6% |
| EPS (diluted) | $0.60 | $0.05 | $1.20 | $0.64 | $1.08 | $0.54 | $1.31 | $1.62 |
| Balance sheet | ||||||||
| Cash and equivalents | $7.89B | $10.3B | $10.9B | $12.6B | $15.7B | $10.2B | $9.57B | $8.72B |
| Total assets | $93.7B | $92.6B | $92.4B | $94.7B | $96.9B | $90.0B | $86.5B | $87.6B |
| Total liabilities | $76.5B | $76.2B | $75.0B | $77.2B | $78.3B | $71.5B | $66.4B | $65.3B |
| Long-term debt | $48.7B | $47.6B | $46.2B | $44.5B | $44.5B | $42.9B | $42.2B | $42.1B |
| Shareholders' equity | $17.1B | $16.3B | $17.4B | $17.4B | $18.6B | $18.5B | $20.1B | $22.3B |
| Cash flow | ||||||||
| Operating cash flow | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B | $1.10B | $3.39B |
| Capital expenditure | $324.0M | $378.0M | $260.0M | $361.0M | $320.0M | $370.0M | $347.0M | $305.0M |
| Free cash flow | $5.27B | $4.06B | $1.69B | $3.56B | $5.99B | $1.60B | $757.0M | $3.09B |
| Dividends paid | $1.22B | $1.22B | $1.26B | $1.26B | $1.26B | $1.26B | $1.28B | $1.29B |
| Share buybacks | $0 | $0 | — | — | — | — | — | — |
From Bristol Myers Squibb's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Bristol Myers Squibb
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Source: Wikipedia — Bristol Myers Squibb
- Headquarters
- Princeton, New Jersey From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- AMGN Amgen
- BAX Baxter International
- BDX Becton Dickinson
- BIIB Biogen
- BSX Boston Scientific
- CAH Cardinal Health
- CI Cigna
- CNC Centene Corporation